SCHEDULE: Janus Henderson Reports Zero Stake in Mereo Biopharma
Beneficial Ownership Report
Janus Henderson Group plc filed an amended Schedule 13G, reporting a 0.0% beneficial ownership in Mereo Biopharma Group PLC as of December 31, 2025.
Summary
- Janus Henderson Group plc (JHG) filed an Amendment No. 7 to Schedule 13G regarding its beneficial ownership in Mereo Biopharma Group PLC.
- JHG, through its various Asset Managers, beneficially owns 0 ordinary shares of Mereo Biopharma Group PLC, representing 0.0% of the class.
- The Asset Managers disclaim any ownership rights to dividends or proceeds from the sale of securities held in the Managed Portfolios, as these rights belong to the Managed Portfolios.
- No individual Managed Portfolio is known to own more than five percent of the ordinary shares of Mereo Biopharma Group PLC.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral disclosure, primarily a compliance update reflecting Janus Henderson Group plc's current 0% beneficial ownership in Mereo Biopharma Group PLC, without providing new operational or financial insights.
Positives
- NA
Negatives
- Janus Henderson Group plc, through its Asset Managers, no longer beneficially owns any ordinary shares of Mereo Biopharma Group PLC, holding 0 shares representing 0.0% of the class.
Risks
- NA
Future Outlook
NA
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
- The Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors, indicating passive ownership or changes in such. A 0% beneficial ownership filing suggests a complete divestment or a reduction below the reporting threshold by Janus Henderson Group plc, a major global asset manager, from Mereo Biopharma Group PLC.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Attorney-in-fact | NA | Kristin Mariani | 2022-12-09 | Appointed as attorney-in-fact for SEC filings on behalf of Janus Henderson Group plc. |
| Attorney-in-fact | NA | Caroline Barotti | 2022-12-09 | Appointed as attorney-in-fact for SEC filings on behalf of Janus Henderson Group plc. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders of Mereo Biopharma Group PLC: May note the complete divestment of shares by a significant institutional investor, which could be interpreted in various ways depending on market context.
- Janus Henderson Group plc clients (Managed Portfolios): The filing clarifies that these clients retain rights to dividends and sale proceeds from securities held in their accounts, and none own more than 5% of Mereo Biopharma.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Date Power of Attorney was executed by Janus Henderson Group plc, appointing attorneys-in-fact for SEC filings. |
| 2025-12-31 | Date of event which requires filing of this statement. |
| 2026-02-17 | Date of signature for the Schedule 13G filing by Janus Henderson Group plc. |
Keywords
Mereo Biopharma Group PLC, Janus Henderson Group plc, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Ordinary Shares, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.